Are Orphan Drugs Treated the Same Across Europe: An Hta Case Study

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.03.1034
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Reimbursement Decision Landscape for Orphan Drugs Across Six Hta Agencies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Hta Studies on Orphan Drugs by Rebratsxmembers

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Psy150 - Inequity of Orphan Drugs Prices in Europe

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy185 - Alternative Methodologies Implemented by Hta Agencies for Orphan Drugs: A Scoping Review

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Examining the Target Population of Orphan Drugs: Are Drugs Exceeding the Intended Purposes of the Orphan Drug Act?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

‘Not All Drugs (And Route) Are Same’

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2018English

Bridging HTA Agencies Across Europe: A Systematic Approach to Categorize Evolving Agencies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Comparison of Recent Hta Appraisals of Orphan Drugs by Nice, SMC and Has in 2015-2017

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Php325 - Orphan Drugs‘ Market Access Challenges in Europe From a German Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy